Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06358300
Status:
COMPLETED
Last Update Posted:
2024-04-10
First Post:
2024-04-04
Brief Title:
Visceral Adiposity Index Differences Between Subtypes of Polycystic Ovary Syndrome
Sponsor:
Uşak University
Organization:
Uşak University
Study Overview
Official Title:
Visceral Adiposity Index Levels in Polycystic Ovary Syndrome Subtypes
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We aimed to investigate visceral adiposity index VAI in patients with different phenotype of policystic ovary syndrome PCOS and to compare healthy controls
Detailed Description:
Polycystic ovary syndrome Metabolic disorders such as insulin resistance dyslipidemia glucose intolerance hypertension and obesity are often accompanied and increased inflammation is the main characteristic of this syndrome While the presence or absence of PCOS was important until recently recent studies have shown that metabolic changes and inflammation occur at different degrees in different subtypes of PCOS Therefore PCOS cases are divided into 4 subtypes These Subtype 1 has hyperandrogenemia oligoanovulation PCO appearance on ultrasonography USG Subtype 2 has hyperandrogenemia oligoanovulation Subtype 3 has hyperandrogenemia PCO appearance on USG and Subtype 4 has oligoanovulation PCO appearance on USG As the subtype number of polycystic ovary syndrome decreases the severity and frequency of metabolic disorders and inflammation accompanying polycystic ovary syndrome increase
Patients with polycystic ovary syndrome often have abdominal obesity which leads to hypertension dyslipidemia impaired glucose tolerance Type 2 Diabetes and metabolic syndrome which predisposes to the development of cardiovascular disease Visceral adiposity is associated with abnormal lipid levels proinflammatory activity insulin resistance and hyperandrogenism Increased visceral adiposity increases the risk of metabolic syndrome Type 2 Diabetes and cardiovascular events in women with PCOS It also aggravates ovulation dysfunction and hyperandrogenism
Visceral adiposity index VAI is a simple marker of visceral adipose tissue dysfunction and visceral adiposity and is associated with insulin resistance hyperinsulinemia hyperandrogenism and anovulation Visceral adiposity index VAI is one of the new methods used to determine visceral adiposity and predict cardiometabolic risks in patients Visceral adiposity index is the strongest marker determining metabolic syndrome in both obese and non-obese PCOS patients Visceral adiposity index is calculated with the formula Waist circumference 3658 188xBMI x Triglyceride081 x 152HDL-C Visceral adiposity index is used in the clinical presentations of PCOS and treatment success It is reported to be a useful marker that enables early detection and intervention of the risk of metabolic syndrome in women Since there are different metabolic effects in different subtypes of PCOS we aimed to investigate whether there is a difference between visceral adiposity indexes in different PCOS subtypes
Patients with polycystic ovary syndrome often have abdominal obesity which leads to hypertension dyslipidemia impaired glucose tolerance Type 2 Diabetes and metabolic syndrome which predisposes to the development of cardiovascular disease Visceral adiposity is associated with abnormal lipid levels proinflammatory activity insulin resistance and hyperandrogenism Increased visceral adiposity increases the risk of metabolic syndrome Type 2 Diabetes and cardiovascular events in women with PCOS It also aggravates ovulation dysfunction and hyperandrogenism
Visceral adiposity index VAI is a simple marker of visceral adipose tissue dysfunction and visceral adiposity and is associated with insulin resistance hyperinsulinemia hyperandrogenism and anovulation Visceral adiposity index VAI is one of the new methods used to determine visceral adiposity and predict cardiometabolic risks in patients Visceral adiposity index is the strongest marker determining metabolic syndrome in both obese and non-obese PCOS patients Visceral adiposity index is calculated with the formula Waist circumference 3658 188xBMI x Triglyceride081 x 152HDL-C Visceral adiposity index is used in the clinical presentations of PCOS and treatment success It is reported to be a useful marker that enables early detection and intervention of the risk of metabolic syndrome in women Since there are different metabolic effects in different subtypes of PCOS we aimed to investigate whether there is a difference between visceral adiposity indexes in different PCOS subtypes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None